New Research Results to be Presented to the American Association of Immunologists

Eagan, MN – March 29, 2005 – Research supporting the ability of WGP^® 3-6 beta glucan to enhance the recovery of white blood cells following bone marrow injury will be presented on April 5 at the annual meeting of the American Association of Immunologists in San Diego.

Cancer and stem cell researchers from the University of Louisville have demonstrated that WGP 3-6 can speed production of critical immune cells following bone marrow damage caused by radiation or chemotherapy. Bone marrow injury and suppression of the immune system is a common side effect of these cancer therapies.

“Preclinical research shows that WGP has promise as a treatment that will help cancer patients undergoing radio or chemotherapy,” said Jun Yan, M.D., Ph.D., a researcher at the James Brown Cancer Center, University of Louisville. “In vivo studies showed that WGP accelerated the recovery of leukocytes following irradiation.”

WGP 3-6 is a food-grade product of Biothera, the immune health company. Biothera manufactures and sells WGP 3-6 as an ingredient in dietary supplements, functional foods, cosmetics and animal nutrition.

Dr. Daniel Cramer from Dr. Yan’s lab will present the findings in a presentation entitled, “Beta Glucan Enhancement of Complement-Mediated Hematopoietic Recovery after Bone Marrow Injury.” The research was supported by grants from the National Cancer Institute, Department of Defense, Kentucky Lung Cancer Research Program, and research gift funds from Biothera.

About Biothera, the Immune Health Company
Biothera is a biotechnology company dedicated to improving immune health. The company's primary focus is developing pharmaceuticals whose unique mechanism of action engages immune cells not normally involved in the fight against cancer. In addition, Biothera’s healthcare group manufactures and markets food-grade immune-enhancing ingredients for the nutritional supplement, functional food, cosmetic and the animal feed and nutrition markets.

Contact:
David Walsh
VP, Communications
Biothera, the Immune Health Company
651-256-4606
dwalsh@biotherapharma.com